Article Text

PDF

A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women
  1. F Lose1,2,
  2. P J Thompson1,3,
  3. D Duffy5,
  4. G A Stewart4,
  5. M-A Kedda1,2,3
  1. 1Asthma and Allergy Research Institute and Centre for Asthma, Allergy and Respiratory Research, University of Western Australia, Perth, WA 6009, Australia
  2. 2Western Australian Institute for Medical Research and the Centre for Medical Research, University of Western Australia, Perth, WA 6009, Australia
  3. 3The CRC for Asthma, Australia
  4. 4Microbiology, School of Biomedical and Chemical Sciences, University of Western Australia, Perth, WA 6009, Australia
  5. 5Genetic Epidemiology Laboratory, Queensland Institute of Medical Research, Brisbane, QLD 4006, Australia
  1. Correspondence to:
    A/Prof P J Thompson
    Asthma and Allergy Research Institute, QEII Medical Centre, Nedlands, WA 6009, Australia; aariaari.uwa.edu.au

Abstract

Background: Airway remodelling is a characteristic feature of chronic asthma and there is evidence that an airway imbalance between levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1) is associated with airway remodelling. On this basis, we hypothesised that polymorphisms in the MMP-9 and TIMP-1 genes were associated with the disease process.

Methods: A number of MMP-9 and TIMP-1 gene polymorphisms were examined in an adult white Australian population of mild (n = 259), moderate (n = 213) and severe (n = 71) asthmatics and non-asthmatic controls (n = 406) using PCR-RFLP and PCR-SSCP analyses.

Results: MMP-9 –1562C>T and 836G>A (Arg279Gln) were not associated with asthma (p⩾0.15) or asthma severity (p⩾0.13), and TIMP-1 434T>C (Phe124Phe) was not associated with asthma in women (p = 0.094) or men (p = 0.207). In this population, MMP-9 −861C>T and TIMP-1 323C>T (Pro87Pro) were not informative (with minor allele frequencies of <1%), and MMP-9 –1702T>A and TIMP-1 595C>T (Ser178Phe) were not detectable. However, a novel polymorphism was detected in the TIMP-1 gene 536C>T (Ile158Ile) which was significantly associated with asthma in women (p = 0.011; OR = 5.54, 95% CI 1.66 to 34.4) but not in men (p = 1.0). 536C>T was found to be in linkage disequilibrium with 434T>C, and haplotype analysis supported an association with asthma (p = 0.014).

Conclusions: This is the first reported association between a polymorphism in the TIMP-1 gene and asthma, and supports the hypothesis that the protease/antiprotease balance has an important role in this common disease.

  • ECM, extracellular matrix
  • EPA, erythroid potentiating activity
  • ESE, exonic splice enhancer
  • HCI, human collagenase inhibitor
  • FEV1, forced expiratory volume in 1 second
  • MMP-9, matrix metalloproteinase-9
  • OR, odds ratio
  • PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism
  • PCR-SSCP, polymerase chain reaction-single strand conformation polymorphism
  • SFRS2, splicing factor, arginine/serine-rich 2
  • SFRS6, splicing factor, arginine/serine-rich 6
  • SNP, single nucleotide polymorphism
  • TIMP-1, tissue inhibitor of metalloproteinases-1
  • matrix metalloproteinase-9 (MMP-9)
  • tissue inhibitor of metalloproteinases-1 (TIMP-1)
  • asthma
  • polymorphism

Statistics from Altmetric.com

Asthma is a complex disease which is influenced by a number of genetic and environmental factors. Abnormal remodelling of the airway wall is a characteristic feature of chronic asthma and is a dynamic process involving extracellular matrix (ECM) production, its degradation and altered structure.1 In this regard, the matrix metalloproteinases (MMPs), a family of proteases that degrade components of the ECM, and their specific inhibitors known as tissue inhibitors of metalloproteinases (TIMPs),2 have both been shown to be particularly important in this process.

Recent studies have described an imbalance in the expression of MMP-9 (also known as collagenase type IV, collagenase type V or gelatinase B) and TIMP-1 (also known as erythroid potentiating activity (EPA) or human collagenase inhibitor) in patients with asthma, implying the importance of this protease/antiprotease interaction in asthma. MMP-9 has been shown to be increased in sputum,3 bronchoalveolar lavage fluid,4 and the subepithelial basement membrane1 of asthma patients compared with normal subjects. Although there is some confusion as to whether TIMP-1 levels remain unaltered5 or are increased6 in asthma, it is consistently reported that the normally stoichiometric ratio of MMP-9 to TIMP-1 is altered in favour of MMP-9 in the asthmatic airway. The increased effective concentration of MMP-9 has been shown to correlate with a fall in forced expiratory volume in 1 second (FEV1).5

The MMP-9 gene is located on chromosome 20q11.2–q13.1 and contains 13 exons with a well defined promoter region. A number of polymorphisms have been described in the MMP-9 coding region and its promoter region. The −1562C>T MMP-9 polymorphism has been shown to result in increased MMP-9 expression7 and to be associated with coronary atherosclerosis,7 increased size of complicated coronary artery lesions,8 and emphysema.9 In contrast, fewer polymorphisms have been described in the TIMP-1 gene which has six exons and maps to Xp11.3–p11.23, and none have been investigated for any functional effects.

On this basis, we hypothesised that polymorphisms in the MMP-9 and, perhaps, TIMP-1 genes may be associated with asthma and/or asthma severity. We investigated this association in a large population of white Australian asthmatic patients and non-asthmatic controls.

METHODS

Subjects

A large number of patients with asthma (n = 543) and non-asthmatic controls (n = 406) participated in the association study and have been described in detail previously.10 Asthma was defined as doctor diagnosed asthma and the non-asthmatic control subjects had no history of asthma or any other chronic respiratory disease. All participants were unrelated white subjects aged between 18 and 89 years. Control subjects were recruited by random mailing and the asthma patients were similarly recruited but supplemented for the more severe patients through physician referrals. All subjects gave written informed consent and completed a comprehensive questionnaire which was used in the assessment of phenotype. Approximately 15 ml of blood was obtained from each participant and lung function was assessed by spirometry. Assessment of atopic status was based on a positive skin prick reaction (weal diameter >3 mm) to at least one of five common aeroallergens: cat, dog, house dust mite, mould mix (Alternaria tenuis, Aspergillus mix, Cladosporium, Penicillin mix) and grass pollen mix (Kentucky Blue, Orchard, Red Top, Timothy, Sweet Vernal, Meadow Fescue, Perennial Rye). The study protocol was approved by the human research ethics committee of the Sir Charles Gairdner Hospital and the research ethics committee at the Alfred Hospital.

Disease severity

To assist in allocating patients to different asthma severity groups, we used criteria slightly modified from those specified by the Australian National Asthma Council11 as well as the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report.12 The following variables were used to assess asthma severity: (1) lung function (% predicted FEV1 when stable); (2) daily inhaled corticosteroid (beclomethasone equivalent) dose when stable; (3) weekly frequency of use of rescue medication over the previous 3 months; (4) weekly frequency of daytime symptoms over the previous 3 months; (5) weekly frequency of night time wakening due to asthma over the previous 3 months; (6) use of oral corticosteroids in the previous 12 months; (7) unplanned visits for asthma care to a general practitioner in the previous 12 months; (8) hospital admissions for asthma in the previous 12 months. Patients were classified as having mild, moderate, or severe asthma with respect to their score for each criterion and were placed in the overall category in which they were classified for the majority of these criteria.

Selection of polymorphisms in MMP-9 and TIMP-1

Several single nucleotide polymorphisms (SNPs) have been described in both the MMP-9 and TIMP-1 genes. For the purpose of our initial investigation into the association between SNPs in these genes and asthma phenotypes, we selected four of the five coding region polymorphisms reported by NCBI (www.ncbi.nlm.nih.gov) in the TIMP-1 gene as these may alter interactions with MMP-9, and four polymorphisms in the MMP-9 gene including one in the coding region and three promoter polymorphisms, the latter of which may be involved in altered gene expression.

Molecular methods

DNA was extracted from buffy coats using a commercially available DNA extraction kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. PCR reactions were carried out in a 25 μl mixture containing at final volume 100 ng genomic DNA; 10 pmol of each primer; 200 μM each of dATP, dCTP, dGTP and dTTP (Promega, Madison, USA); 1–2 mM MgCl2; 1×PCR buffer (Qiagen); 1×Q solution (Qiagen); and 1U Taq polymerase (Qiagen). Amplification conditions involved denaturation of samples at 94°C for 5 minutes followed by 30–37 cycles of denaturation at 94°C for 30 seconds, annealing (temperatures detailed in table 1) for 30 seconds, and extension at 72°C for 30 seconds with a final extension step of 72°C for 10 minutes. The restriction enzymes used to characterise the MMP-9 −1562C>T, −861C>T, 836G>A and TIMP-1 536C>T polymorphisms are detailed in table 1. Digested PCR products were electrophoresed on agarose gels (2–4%) (Amresco, OH, USA). The TIMP-1 323C>T, 434T>C and 595C>T polymorphisms and the MMP-9 −1702T>A polymorphism were investigated using SSCP analysis on MDE polyacrylamide gels (BMA, ME, USA). Gels were electrophoresed at 150 V at 4°C and 24°C, respectively, and visualised by silver staining. All samples displaying variant band patterns were sequenced to confirm genotypes. A random sample of subjects was re-genotyped for all informative polymorphisms including common alleles of the TIMP-1 536C>T polymorphism. All rare alleles of the TIMP-1 536C>T polymorphism were resequenced at least twice.

Table 1

 PCR primers and restriction digests

Statistical analysis

Genotype and allele frequencies were calculated for each of the patient groups. Univariate comparisons of allele and genotype distribution were performed using χ2 tests and logistic regression analysis in the R statistics program,13 and association was assessed under a multiplicative penetrance model. Hardy-Weinberg equilibrium analysis for each group was evaluated by the exact test, implemented in the R statistics program. Linkage disequilibrium between the markers and associations between haplotypes and asthma were assessed using Cocaphase.14 Cocaphase uses an expectation-maximisation (algorithm) approach to establish haplotype probabilities for each person, which are applied as weights in a logistic regression association analysis.

The p values presented are unadjusted. The haplotype analysis combines evidence from all SNPs in a gene, so tests of significance correctly adjust for the number of SNPs tested per gene. The Bonferroni corrected threshold (for an experiment-wide type I error rate of 0.05) for the haplotype tests is therefore 0.025 and the individual SNP tests of association are “protected” by the haplotype tests.

Analysis of putative exonic splice enhancer (ESE) sites

The TIMP-1 gene sequence was analysed using the exonic splice enhancer (ESE) detection program ESEfinder15 in order to predict the functional significance of the novel 534C>T polymorphism.

RESULTS

Subjects

In total, 543 patients with asthma and 406 non-asthmatic controls participated in the study. All subjects were white, and patients with asthma were further subdivided by disease severity. The demographic data of the study population are shown in table 2. All groups had similar age and sex distributions, although the asthma group as a whole had a significantly higher percentage of atopic subjects (83%) than the non-asthmatic control group (51%; p<0.0001). Daytime symptoms of asthma occurred, on average, 3.9 times per week in individuals with mild asthma, 6.8 times per week in those with moderate asthma, and 9 times per week in subjects with severe asthma. Less than half the patients with mild asthma woke from sleep due to their asthma, while all patients with severe asthma woke from sleep most nights due to their asthma. Unplanned visits to the family doctor for asthma over the previous 12 months ranged from 0.51 per year in patients with mild asthma to 1.4 per year in patients with moderate asthma and 4.2 per year in patients with severe asthma. Hospital admissions over the previous 12 months occurred in less than 5% of patients with mild asthma, in 30% of patients with moderate asthma, and in 70% of patients with severe asthma.

Table 2

 Demographic data of study population

Polymorphisms

The MMP-9 −1562C>T, −861C>T and 836G>A (Arg279Gln) and TIMP-1 536C>T (Ile158Ile) polymorphisms were investigated using PCR-RFLP analysis and the MMP-9 −1702T>A, and TIMP-1 323C>T (Pro87Pro), 434T>C (Phe124Phe) and 595C>T (Ser178Phe) polymorphisms were investigated using PCR-SSCP analysis. Table 3 summarises the allele and genotype frequencies obtained for all polymorphisms studied.

Table 3

 Allele and genotype distribution in asthma patients and non-asthmatic controls

MMP-9

−1562C>T and 836G>A (Arg279Gln)

All population groups were in Hardy-Weinberg equilibrium for the MMP-9 −1562C>T and 836G>A (Arg279Gln) polymorphisms, and there were no associations between either of the polymorphisms and asthma (−1562C>T and 836G>A, p  =  0.152), asthma severity (−1562C>T, p = 0.76; 836G>A, p = 0.31), or atopy (−1562C>T, p = 0.49; 836G>A, p = 0.25). Using a multiplicative penetrance model, the odds ratio (OR) for −1562C>T was 1.01 (95% CI 0.77 to 1.33) and 1.16 (95% CI 0.96 to 1.41) for 836G>A, so we were able to exclude, with 95% certainty, true effect sizes of 1.33 and 1.41 for these polymorphisms. The MMP-9 836A>G and −1562C>T polymorphisms were in strong linkage disequilibrium (D′cases  =  0.89, D′controls  =  0.88; p = 3e−58), as reported previously,16 and there was no association between asthma and MMP-9 haplotypes (p = 0.62).

−861C>T and −1702T>A

In this population the −861C>T polymorphism was not informative (minor allele frequency <1%) and the −1702T>A polymorphism could not be detected using PCR-SSCP analysis.

TIMP-1

As the TIMP-1 gene is on the X chromosome, the results obtained were segregated by sex.

536C>T (Ile158Ile)

A TIMP-1 534A>G (Ile158Val) exon 6 missense mutation has previously been reported in the NCBI SNP database (SNP ID: rs1803571) and shown to alter a FokI restriction site. Genotypes based upon restriction analysis of this site were confirmed by sequence analysis. However, the 534A>G polymorphism was not detected in this population. Instead, our sequence analyses revealed a C>T polymorphism at position 536, two bases downstream of the previously described polymorphism (see fig S1 available online at http://www.thoraxjnl.com/supplemental). The novel 536C>T polymorphism did not change the translated amino acid (Ile158Ile), although it altered the previously reported 534A>G (Ile158Val) FokI restriction recognition site polymorphism (fig 1). Importantly, this new polymorphism was found to be associated with asthma in women (p = 0.011) but not in men (p = 1.0), particularly in women with mild asthma (p = 0.009; OR 5.54, 95% CI 1.66 to 34.4). The asthma population was not in Hardy-Weinberg equilibrium for this polymorphism (p = 0.001), possibly due to the effects of ascertainment on a trait associated locus, nor was the polymorphism associated with atopy (p = 0.589).

Figure 1

 Partial TIMP-1 sequence illustrating (A) the wild type sequence, (B) the previously reported 534A>G (Ile158Val) polymorphism, altering a FokI restriction enzyme recognition site (in bold) and detected by PCR-RFLP analysis, and (C) the novel 536C>T (Ile158Ile) polymorphism reported in this study, which also alters the FokI restriction enzyme recognition site.

Analysis of the 536C>T polymorphism with the ESE detection program ESEfinder15 predicted alterations in ESE sites. The substitution of a C for a T nucleotide at position 536 resulted in a reduction in score value for the SC35 (also known as SFRS2; OMIM: 600813) SR protein from 4.367 to 3.483. This is a relatively large reduction. However, both scores are still significantly higher than the binding threshold for SC35 (2.385) and are therefore unlikely to result in any change in enhancer activities. In addition, the 536C>T substitution is predicted to result in the complete loss of an SRp55 (also known as SFRS6; OMIM: 601944) site, TCCATC, that possessed a reasonably high binding score value of 3.223 (SRp55 threshold 2.676).

434T>C (Phe124Phe)

The TIMP-1 exon 5 434T>C (Phe124Phe) polymorphism17 was not found to be associated with asthma in this population (women: OR = 0.73, 95% CI 0.41 to 1.29; p = 0.094; men: OR = 0.56, 95% CI 0.23 to 1.38, p = 0.207) or with atopy (p = 0.235). However, a χ2 test showed that the 434T>C polymorphism was in linkage disequilibrium with the novel 536C>T polymorphism (D′cases = 0.24, D′controls = 0; p = 0.06) and, importantly, there was an association between asthma and the TIMP-1 haplotype (table 4) (χ2 = 10.67, p = 0.014).

Table 4

 Distribution of TIMP-1 haplotype in asthmatic subjects

323C>T (Pro87Pro) and 595C>T (Ser178Phe)

The TIMP-1 323C>T (Pro87Pro) polymorphism was uninformative in this population (minor allele frequency <1%), and the 595C>T (Ser178Phe) polymorphism could not be detected using PCR-SSCP analysis.

DISCUSSION

Chronic asthma is characterised by abnormal remodelling and altered airway function due, in part, to altered deposition of the ECM which may arise as the result of an imbalance in the expression of MMP-9 and TIMP-1. This study was designed to investigate associations between several polymorphisms in the MMP-9 and TIMP-1 genes and asthma in a large population of mild, moderate and severe asthmatics and non-asthmatic controls. Most importantly, in this comprehensive study we have demonstrated a significant association between a novel polymorphism in the TIMP-1 gene (536C>T (Ile158Ile)) and asthma in women, as well as an association between the TIMP-1 haplotype and asthma. While a number of polymorphisms have been described and functionally characterised in the MMP-9 gene, few have been described in the TIMP-1 gene and none have been investigated for functional effects.

No associations between asthma, asthma severity, or atopy and two polymorphisms in MMP-9 (−1562C>T and 836G>A) and one polymorphism in TIMP-1 (434T>C) were detected. Although the MMP-9 promoter polymorphism −1562C>T has previously been shown to result in an increase in MMP-9 expression7 and to be associated with various non-asthmatic diseases,7–9 suggesting that it may be important in tissue remodelling of the ECM, we were unable to detect an association with asthma; these findings agree with studies performed in a small Eastern European population.18 However, the polymorphic T allele appeared to be more common in severe asthmatics although this was not statistically significant, due perhaps to the relatively small numbers in this phenotypic group. The MMP-9 catalytic region 836G>A (Arg279Gln) missense variant was initially described in a Swedish population,16 but the allele frequencies observed in our study suggest that the G allele is actually the minor allele (q = 0.34).

We did not detect the previously described TIMP-1 534A>G (Ile158Val) exon 6 missense mutation (SNP ID: rs1803571) in this population. However, we did detect a novel C>T polymorphism at position 536 of the TIMP-1 gene, and found an association between this polymorphism and asthma in women (p = 0.011) in our population. The silent TIMP-1 polymorphism 434T>C (Phe124Phe) has been reported to be associated with abdominal aortic aneurysm in women (p = 0.002),15 but we found no association between this polymorphism and asthma, asthma severity, or atopy. Importantly, we have shown that the 434T>C polymorphism was in linkage disequilibrium with the novel 536C>T polymorphism (p = 0.06) and there was an association between asthma and TIMP-1 haplotype (p = 0.014), further supporting our findings of an association between a TIMP-1 polymorphism and asthma.

Until recently, polymorphisms which did not alter the amino acid sequence of a protein were considered to be of little consequence, but a number of studies have indicated that all types of variation may be important in human genetic disease.19,20 The 536C>T polymorphism is located 18 nucleotides into exon 6 of the TIMP-1 gene, the only region responsible for binding to and preventing activation of MMP-9.21 However, this variant does not alter the amino acid sequence of the TIMP-1 protein and is therefore not predicted to affect protein structure. Nevertheless, Krawczak and colleagues19 estimate that at least 15% of point mutations resulting in human genetic disease cause RNA splicing defects, possibly from the disruption of short sequences within exons known as ESE that promote splicing,22 and it has been shown that a single nucleotide substitution in an ESE can result in failure of serine/arginine-rich non-small nuclear ribonucleoprotein (non-snRNP) splice factors (the SR proteins) to recognise the ESE, leading to exon skipping.23,24 Prediction analysis of the 536C>T polymorphism using the ESE detection program ESEfinder15 predicted alterations in an SC35 site, reducing the binding score of this protein, and the complete loss of an SRp55 site, suggesting that these changes may affect enhancer binding and hence splicing of the gene. However, while it is interesting to speculate on the functional significance of alterations to putative ESE sites, no TIMP-1 splice variants have been reported to date, and it will be important to confirm the effect of this polymorphism on TIMP-1 and its relationship to asthma. It is also worth noting that the wild type C allele is conserved in both mouse and rat (Ensembl: www.ensembl.org), which may imply a functional role for this nucleotide, although it is also possible that the 536C>T polymorphism is in linkage disequilibrium with a functional polymorphism elsewhere in the TIMP-1 gene.

Although knockout experiments in mice have provided support for a role for MMP-9/TIMP-1 imbalance in asthma,25 the physiological significance of MMP-9 and TIMP-1 in asthma has been debated for some time. Three studies, each involving more than 20 asthmatic subjects, have reported a statistically significant increase in the levels and/or activity of MMP-9 compared with controls,6,26,27 and a number of smaller studies support these findings.5,28,29 The main area of discrepancy between many studies on the MMP-9/TIMP-1 system and asthma involve TIMP-1 expression levels. Some groups have reported an increase in the level of TIMP-1 in asthmatic subjects,6 whilst others have observed no differences in TIMP-1 expression between asthmatics and controls.5,29 It has been shown that, regardless of TIMP-1 levels, the normally stoichiometric ratio of MMP-9 to TIMP-1 is unbalanced in favour of MMP-9, and this has been negatively correlated with FEV1 in asthmatics.6 It is also possible that the actual level of expression of TIMP-1 is not the most important factor in asthma. Instead, an alteration in the structure or function of TIMP-1 may be allowing uncontrolled MMP-9 activity.

In conclusion, we have investigated the association between a number of polymorphisms in both MMP-9 and TIMP-1 genes and asthma, asthma severity and atopy using a large, carefully phenotyped white Australian population. We have shown that four MMP-9 and TIMP-1 polymorphisms were not associated with asthma, but a novel polymorphism in the TIMP-1 gene (536C>T (Ile158Ile)) was significantly associated with mild asthma in women and TIMP-1 haplotypes were also associated with asthma. The functional significance of the 536C>T polymorphism has still to be determined, but its association with asthma severity highlights the potential importance of proteases and antiproteases in this socioeconomically important disease.

Acknowledgments

The authors thank the patients who participated in this study, the NH&MRC for financial support, the staff at the Sir Charles Gairdner and Alfred Hospitals who assisted with clinical data collection, and Penelope Worsley, Kirrily O’Hara, Bernadette Bradley and Jing Shi for preparation of DNA and technical assistance.

REFERENCES

View Abstract
  • The figure is available as a downloadable PDF (printer friendly file).

    If you do not have Adobe Reader installed on your computer,
    you can download this free-of-charge, please Click here

     

    Files in this Data Supplement:

    • [view PDF] - Supplemental figure: Sequence analysis of the novel 536C>T polymorphism.
      i) CC homozygote
      ii) CT heterozygote
      iii) TT homozygote

Footnotes

  • This project was funded by the Asthma and Allergy Research Institute and the National Health and Medical Research Council of Australia

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.